Finally, zoledronic acid-treated macrophages release lower levels of angiogenic cytokines (i.e., VEGF, bFGF, HGF, and PDGF) and down-regulate the expression of vasculogenic markers, i.e., FVIII-RA, VEGFR2, Tie2/Tek, and VE-cadherin suggesting that this strategy may be useful to counteract vasculogenesis mimicry mediated by MM macrophages [103] (Figure 2f). The gene discussed is FGF2; the disease is Miyoshi myopathy.